Suspended PHASE1 INTERVENTIONAL 1-arm NCT02117336

Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

A Phase I/Ib Study of P1446A-05 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

Sponsor: Dana-Farber Cancer Institute

Conditions Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Interventions P1446A-05

Updated 6 times since 2017 Last updated: Sep 2, 2014 Started: Jun 30, 2014 Primary completion: Oct 31, 2016 Completion: Mar 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

Sponsor decision not related to patient safety

Listed as NCT02117336, this PHASE1 trial focuses on Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and remains suspended. Sponsored by Dana-Farber Cancer Institute, it has been updated 6 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Suspended PHASE1
Jul 2024 — Sep 2024 [monthly]

Suspended PHASE1
Jan 2021 — Jul 2024 [monthly]

Suspended PHASE1
Jun 2018 — Jan 2021 [monthly]

Suspended PHASE1
Feb 2017 — Jun 2018 [monthly]

Suspended PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Suspended PHASE1

First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dana-Farber Cancer Institute
Norris Cotton Cancer Center
Piramal Enterprises Limited

Data source: Piramal Enterprises Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Lebanon, United States